Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Department of Paediatrics at the University of Oxford is delighted to announce that Anindita Roy has been named Professor of Paediatric Haematology at the University of Oxford.

Andi leads a research group based at the MRC Weatherall Institute of Molecular Medicine (WIMM), where the main aim is to understand the origins of childhood leukaemia, especially the treatment resistant subtypes such as infant leukaemia. She is currently a Wellcome Trust Clinical Research Career Development Fellow and an MRC Investigator.

Andi trained first as a Paediatrician (in India and then UK), before focusing her clinical and academic career in Paediatric Haematology. Her previous academic placements include LLR Clinical Training Fellowship (PhD 2007-2011, Imperial College London), NIHR Academic Clinical Lectureship in Paediatric Haematology (2011-2015, Imperial College London) and Bloodwise Clinician Scientist Fellowship (2015-2019), University of Oxford).

Andi says: “It has always been a long-term career aspiration to be an academic paediatric haematologist and I am delighted and honoured to be appointed as Professor by the Department. I am very grateful for the support of many excellent mentors, the members of my research group and funding bodies; without whose help this achievement would not have been possible. And of course, my family.”

“Being embedded within the Medical Sciences Division (MSD) at Oxford, provides me with the ideal scientific and clinical environment to perform high quality research, including the necessary infrastructure for global outreach. I am surrounded by collaborative and supportive mentors and peers, who allow me to thrive within the excellent research framework of the department. I am passionate about training the next generation of clinician scientists; and play an active role in mentoring and nurturing this group.”

Recent stories

Oxford spin-out raises $90 million to advance new treatments for blood cancers

Alethio Therapeutics, a University of Oxford spin-out co-founded by Professors Adam Mead and Beth Psaila, has secured $90 million (£67 million) in oversubscribed Series A financing to develop a new generation of therapies for myeloproliferative neoplasms (MPNs).

New technology helps decode the genetic changes behind disease

Researchers from the Milne, Hughes and Davies Groups have developed a new technology that can reveal new therapeutic targets from common genetic variants linked to disease.

Everyday DNA damage reveals a hidden weakness in some cancers

Researchers in the Chapman Group have discovered why cancer cells lacking a protein called ATM are particularly vulnerable to a class of cancer drugs known as PARP inhibitors, solving a scientific puzzle that has challenged researchers for nearly 20 years.

Professor Marella de Bruijn receives MRC Programme Award

Congratulations to Professor de Bruijn, who has been awarded funding from the UKRI Medical Research Council to investigate how the first blood stem cells formed in the embryo acquire their exceptional regenerative potential, with the aim of informing future stem cell therapies.

Professor Bethan Psaila wins ISEH Janet Rowley Award

Congratulations to Professor Psaila, who has received the 2026 Janet Rowley Award from the International Society for Experimental Hematology, in recognition of her outstanding contributions in the field of experimental haematology.

Professor KJ Patel awarded Royal Society Buchanan Medal

Congratulations to Professor Patel, who has received the Buchanan Medal, which recognises distinguished contributions to the biomedical sciences.